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Background: Sugammadex has a unique mechanism of action and is widely used because of its safety and
efficacy. A few recent reports have described allergic reactions to clinical doses of sugammadex. We hereby
describe another series of cases of possible anaphylaxis to sugammadex.
Case presentation: We present three suspected cases of sugammadex-induced anaphylactic shock, including a
13-year-old boy who underwent laparoscopic appendectomy, a 75-year-old woman who underwent left knee
arthroplasty, and a 34-year-old man who underwent left pansinectomy for sinobronchitis. All three patients received
general anesthesia with rocuronium and their tracheas were intubated. Shortly after injection of sugammadex for
reversal of rocuronium, all of them experienced a decrease in blood pressure along with mucocutaneous erythema.
In the most severe case, reintubation after extubation was required due to difficulty in manual ventilation. All
patients recovered with anti-allergic therapy. On later investigation, all three patients had a positive skin reaction
to sugammadex.
Conclusion: Our results suggest that physicians using sugammadex should be aware of the possibility of
sugammadex-induced anaphylaxis.
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Sugammadex is widely used in more than 60 countries,
including the European Union and Japan, for reversal of
the effects of the steroidal neuromuscular blocking agents,
rocuronium and vecuronium. Sugammadex acts by encap-
sulation of the rocuronium molecule, such that no more
rocuronium is available for binding with nicotinic ace-
tylcholine receptors in the neuromuscular junction. This
action of sugammadex for antagonizing rocuronium is
completely different from that of acetylcholinesterase in-
hibitors, such as neostigmine. Sugammadex is generally
thought to be a relatively safe and well-tolerated drug,
partly due to the lack of some undesirable effects [1,2].
However, confirmed cases of allergic reactions to clinical
doses of sugammadex were recently reported [3-8]. We
describe 3 cases in which allergic and positive skin test re-
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A 13-year old, 40 kg, 159 cm boy underwent laparosco-
pic appendectomy. Anesthesia was induced with 80 mg
propofol, 0.33 μg/kg/min remifentanil, and 30 mg rocur-
onium. After an uneventful intubation, anesthesia was
maintained with sevoflurane and remifentanil. About
15 minutes after intubation, 50 mg flurbiprofen axetil
was administered. During the surgery, oxygen saturation
was maintained in the high 90% range and ETCO2 was
within normal limits. Baseline blood pressure (BP) was ap-
proximately 116/78 mm Hg, remaining in the 90/40 mm
Hg range for most of the case. Heart rate (HR) remained
at 50 to 60 bpm. The total operation time was 118
minutes. Before extubation, sugammadex 2 mg/kg was
injected to antagonize residual neuromuscular block-
ade. Shortly after the injection, the patient’s trachea wasral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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After extubation, the patient demonstrated global swell-
ing of the face and a low consciousness level. At this
point, his blood pressure fell to unmeasurable values and
he developed tachycardia of between 150 and 160 bpm.
Suspecting a possible allergic reaction to sugammadex, he
was treated with 100 mg hydrocortisone and 0.1 mg
adrenaline IV. The patient needed to be re-intubated be-
cause of difficulty with bag mask ventilation. Blood gas
analysis showed hypercapnea (PCO2 = 66.4 mmHg). His
trachea was re-intubated after re-induction of anesthesia
with 80 mg propofol and 50 mg rocuronium. Additional
treatment with 200 mg aminophylline and 200 mg hy-
drocortisone was given after the intubation, because the
occurrence of an asthmatic attack could not be excluded.
The patient stayed in the ICU until his trachea was extu-
bated 17 hours after the event. A prick test with dilutions
of propofol, rocuronium, ropivacaine, flurbiprofen axetil,
and sugammadex was performed 7 weeks after the op-
eration, which showed an immediate reaction only to
sugammadex (Table 1).
Case 2
A 75-year-old, 71 kg, 152 cm woman underwent left
knee arthroplasty. General anesthesia was induced with
130 mg propofol, 0.2 μg/kg/min remifentanil, and 40 mg
rocuronium. Following tracheal intubation, anesthesia
was maintained with sevoflurane and remifentanil. Ten
minutes after induction of general anesthesia, her BP
and HR decreased to 70/50 mmHg and 50 bpm, respect-
ively. Incremental doses of ephedrine (8 mg × 2), 0.2 mg
phenylephrine and 0.5 mg atropine were administeredTable 1 Results of postoperative allergy testing in the three p
Type of allergy test Drug Concentratio















Vial concentrations: propofol 10 mg/ml, rocuronium 10 mg/ml, ropivacaine 7.5 mg/ml,intravenously. Both BP and HR responded well to these
treatments and increased to 150/70 mm Hg and 75 bpm,
respectively. Twenty minutes before the end of surgery,
50 mg flurbiprofen axetil was administered. The total op-
eration time was 99 minutes. Before extubation, sugam-
madex 2.8 mg/kg was administered. Three minutes after
the injection of sugammadex, her systolic BP fell to 40/
undetectable mm Hg, together with thoracic erythema,
with no response to 0.2 mg phenylephrine injection. No
respiratory symptoms, such as wheezing and high airway
resistance, were observed. Suspecting a possible allergic
reaction to sugammadex, we intravenously administered
0.5 mg adrenaline, 5 mg chlorpheniramine maleate, 50 mg
ranitidine hydrochloride, and 300 mg hydrocortisone. Her
BP gradually increased to 160/80 mmHg after these treat-
ments. The patient was transferred to the intensive care
unit (ICU) without extubation. Her trachea was extubated
15 hours later in the ICU when she was fully awake and
hemodynamically stable. She was transferred out of the
ICU the following morning. Four weeks after the oper-
ation, an intradermal allergy test with dilutions of propo-
fol, rocuronium, flurbiprofen axetil, and sugammadex was
performed. A 1:1000 dilution of all the drugs showed a
negative reaction. However, a 1:100 dilution of sugamma-
dex resulted in a positive reaction (Table 1).
Case 3
A 34-year old, 62 kg, 159 cm man underwent left pansi-
nectomy for sinobronchitis. Anesthesia was induced with
100 mg propofol, 0.25 μg/kg/min remifentanil, and 40 mg
rocuronium. Following tracheal intubation, anesthesia was
maintained with sevoflurane and remifentanil. Duringatients with suspected anaphylaxis
















flurbiprofen axetil 10 mg/ml, pentazocine 15 mg/ml, sugammadex 100 mg/ml.
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saturation, and ETCO2 were within normal ranges. The
total operation time was 59 minutes. At the end of sur-
gery, 50 mg flurbiprofen axetil, 15 mg pentazocine, and
sugammadex 3.2 mg/kg were injected. One minute after
the injection but before extubation, the patient devel-
oped intense erythema all over the body, especially on
the face and chest. Simultaneously, BP decreased from
100/60 to 70/40 mmHg, with no respiratory symptoms.
BP recovered to 100/60 mmHg after 4 mg ephedrine
hydrochloride injection, and the patient was transferred
to the recovery unit. Erythema disappeared after treat-
ment with 5 mg chlorpheniramine maleate and 50 mg
ranitidine hydrochloride administered intravenously. The
patient was transferred out of the recovery room 1 hour
after the event and discharged home 6 days later. An
intradermal test for flurbiprofen axetil, pentazocine, and
sugammadex allergy was performed about 7 weeks after
the operation. As shown in Table 1, a 1:1000 dilution of
sugammadex induced flare, while a 1:100 dilution of
sugammadex induced both flare and wheal.
Discussion
The etiological diagnosis of perioperative anaphylaxis re-
lies on a triad of evidences, including clinical, biological,
and allergological evidence [9]. We report here three
cases, in which both clinical symptoms and positive skin
test reactions were observed in response to sugammadex
injection.
The first line of evidence for diagnosing anaphylaxis
includes clinical signs. The National Institute of Allergy
and Infectious Disease (NIAID) and the Food Allergy
and Anaphylaxis Network (FAAN) proposed clinical cri-
teria for diagnosing anaphylaxis [10]. All three of our
cases fulfilled these criteria, as evidenced by the acute
onset of symptoms, with involvement of the skin and
hypotension.
The second line of evidence for diagnosing anaphyl-
axis is biological assessment, including plasma hista-
mine and tryptase measurements. Typically, anaphylaxis
results from mast cell activation, which causes release of
mast cell tryptase into the circulation, although a variety
of other pathways, including basophil or complement acti-
vation, may combine to produce anaphylaxis. We were
unable to perform any blood tests in our patients. The
currently available tryptase assay has a relatively low sensi-
tivity; hence, some cases of anaphylaxis might be missed
[11]. However, given the high specificity of tryptase assay
[12], such assessment should be done for diagnosing ana-
phylaxis. During anaphylaxis, tryptase peaks by approxi-
mately 1 h and its half-life in the circulation is about 2 h
[11], suggesting that elevation of tryptase can still be seen
at least 1-2 hours after onset of the reaction, by which
time the patient should be stabilized.Skin tests, the third line of evidence, remain the gold
standard for the detection of IgE-mediated reactions, and
involve exposure of the mast cells of the skin of patients
who experience anaphylaxis to the suspected allergen [13].
In previous reports, either skin-prick [3,4] or intradermal
[7,8] tests were performed to detect hypersensitivity to
sugammadex. However, there are no established guide-
lines with respect to skin testing for hypersensitivity to
sugammadex. Moreover, it is still unknown which of the
two tests is superior. In our three cases, we performed
prick or intradermal tests in the operation room several
weeks after the incidents, with drugs to treat anaphylaxis
readily available. The results showed a positive reaction to
only sugammadex in all cases. We chose relatively low
concentrations (i.e., 1:1000 or 1:100) of sugammadex for
both prick and intradermal tests to avoid false-positive re-
actions, because it is known that intradermal tests some-
times produce false-positive reactions [14]. A recent study
showed that dilutions of 100 mg/ml sugammadex at 1:77
and 1:770 for intradermal tests did not cause skin irrita-
tion or false positive reactions in 11 volunteers, suggesting
that 1:100 and higher dilutions of sugammadex are not
likely to produce false-positive reactions [15]. However,
it was difficult to exclude the possibility that the positive
reaction to sugammadex might have been a non-specific
cutaneous irritant effect, because of the lack of a positive
control skin test with histamine. In addition to skin tests,
tests for serum-specific IgE antibodies and basophil ac-
tivation using flow-cytometry may also be useful for the
diagnosis of anaphylaxis [11,16,17]. Taken together, the
immediate development of anaphylaxis in response to
sugammadex and the results of skin tests were highly sug-
gestive of sugammadex-induced anaphylactic shock, al-
though biological assessments and positive control skin
tests were lacking.
None of our patients had prior exposure to sugam-
madex. Cyclodextrins, one of the components of sugam-
madex preparations, are present in various foods, which
may partly explain the cross-reaction with sugammadex.
A recent report suggested that the appropriate dose of
sugammadex for reversal of rocuronium should be de-
termined by the results of neuromuscular monitoring
[18]. However, we did not monitor neuromuscular trans-
mission in our patients.
Sugammadex-induced anaphylaxis typically presents
when the patient is already extubated and is being trans-
ferred to the hospital bed, PACU, ICU, etc. [3], time points
when the patient is typically less monitored. Therefore,
rapid diagnosis and appropriate treatment of anaphylaxis,
including administration of adrenaline, oxygen, and large
volumes of crystalloids, are required. In the current re-
port, patients 1 and 2 were treated with 0.1 and 0.5 mg
adrenaline IV, respectively. Although the maximum intra-
venous bolus dose of adrenaline recommended by recent
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[17,19], the IV bolus dose of 0.5 mg adrenaline adminis-
tered to case 2 appears to be a larger dose than that rec-
ommended by guidelines.
The Japanese Society of Anesthesiologists has issued a
warning about sugammadex-induced anaphylactic shock
three times since March 2011. The latest one, issued in
June 2013, included 95 cases of sugammadex-related aller-
gies that occurred between April 2010 and January 2013,
although with no incidents of death. In all 95 cases, the
relationship between the reaction and sugammadex was
definitively ascertained by the anesthesiologists. Seventy-
eight out of 95 cases fulfilled the validated criteria for ana-
phylaxis [10]. The incidence rate of anaphylactic reactions
due to sugammadex was estimated as 29 per million cases,
based on the estimated number of patients (3.09 millions)
in whom sugammadex was injected during the survey
period. The alert also pointed out that the incidence rate
may have been underestimated, because the survey was
based on spontaneous reports from anesthesiologists and
not on prospective studies. It is uncertain whether this in-
cidence rate is higher in Japan than in other countries, be-
cause there is no epidemiological survey regarding this so
far. The other possibility is that these warnings may sim-
ply reflect a high level of sugammadex usage in Japan. The
drug company, MSD (Tokyo, Japan), has reported that
sugammadex usage in Japan in 2010, in terms of monetary
value, was more than 4 times higher than that in Spain,
the country that showed the second highest usage in the
world.Conclusion
We would advise physicians using sugammadex to be aware
of the possibility of sugammadex-induced anaphylaxis.Consent
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